Published in Adv Drug Deliv Rev on November 23, 2005
Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J Exp Med (2010) 1.41
Heterotypic RPE-choroidal endothelial cell contact increases choroidal endothelial cell transmigration via PI 3-kinase and Rac1. Exp Eye Res (2006) 1.02
Enhanced differentiation of retinal progenitor cells using microfabricated topographical cues. Biomed Microdevices (2010) 0.97
Visualization of retinal vascular structure and perfusion with a nonconfocal adaptive optics scanning light ophthalmoscope. J Opt Soc Am A Opt Image Sci Vis (2014) 0.95
Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes. Expert Opin Drug Deliv (2010) 0.94
Tailor-made pentablock copolymer based formulation for sustained ocular delivery of protein therapeutics. J Drug Deliv (2014) 0.86
Novel thermosensitive pentablock copolymers for sustained delivery of proteins in the treatment of posterior segment diseases. Protein Pept Lett (2014) 0.86
Consequences and utility of the zinc-dependent metalloprotease activity of anthrax lethal toxin. Toxins (Basel) (2010) 0.84
Suppression of experimental choroidal neovascularization by curcumin in mice. PLoS One (2012) 0.82
Clearance of autophagy-associated dying retinal pigment epithelial cells - a possible source for inflammation in age-related macular degeneration. Cell Death Dis (2016) 0.81
Novel pentablock copolymer-based nanoparticulate systems for sustained protein delivery. AAPS PharmSciTech (2014) 0.81
PPAR-alpha Ligands as Potential Therapeutic Agents for Wet Age-Related Macular Degeneration. PPAR Res (2008) 0.80
Quantification of choroidal neovascularization vessel length using optical coherence tomography angiography. J Biomed Opt (2016) 0.79
Optimization of novel pentablock copolymer based composite formulation for sustained delivery of peptide/protein in the treatment of ocular diseases. J Microencapsul (2016) 0.78
The effects of ranibizumab injections on fluorescein angiographic findings and visual acuity recovery in age-related macular degeneration. Clin Ophthalmol (2014) 0.75
Evaluation of tissue interactions with mechanical elements of a transscleral drug delivery device. Pharmaceutics (2012) 0.75
Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci (2011) 2.53
Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol (2010) 1.82
Imaging pulsatile retinal blood flow in human eye. J Biomed Opt (2008) 1.73
Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol (2009) 1.64
Correlation of visual acuity and macular thickness measured by optical coherence tomography in patients with persistent macular edema. Retina (2010) 1.56
Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology (2013) 1.52
Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema. Clin Ophthalmol (2011) 1.46
Sutureless 23-gauge versus 20-gauge vitrectomy with silicone oil injection in rhegmatogenous retinal detachment. Retina (2012) 1.46
Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci (2011) 1.46
Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology (2012) 1.32
Cardiovascular disease, its risk factors and treatment, and age-related macular degeneration: Women's Health Initiative Sight Exam ancillary study. Am J Ophthalmol (2007) 1.26
Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina (2006) 1.25
Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology (2005) 1.22
Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci (2010) 1.17
Ocular changes after photodynamic therapy. Invest Ophthalmol Vis Sci (2006) 1.17
Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells. Invest Ophthalmol Vis Sci (2006) 1.16
Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol (2009) 1.13
Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression. Ophthalmology (2004) 1.13
Ranibizumab. Nat Rev Drug Discov (2006) 1.08
Trypan blue: effect on retinal pigment epithelial and neurosensory retinal cells. Invest Ophthalmol Vis Sci (2005) 1.07
Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment. Ophthalmology (2004) 1.07
Uncertain compassion in using a drug before the risks and benefits are known. Arch Ophthalmol (2006) 1.05
Characteristics of untreated AIDS-related cytomegalovirus retinitis. II. Findings in the era of highly active antiretroviral therapy (1997 to 2000). Am J Ophthalmol (2008) 1.02
Assessment of the differences in pharmacokinetics and pharmacodynamics between four distinct formulations of triamcinolone acetonide. Retina (2013) 0.97
Mitochondrial DNA variants mediate energy production and expression levels for CFH, C3 and EFEMP1 genes: implications for age-related macular degeneration. PLoS One (2013) 0.96
Intravitreous dexamethasone effects on different patterns of diabetic macular edema. Arch Ophthalmol (2010) 0.95
Safety profile of ocriplasmin for the pharmacologic treatment of symptomatic vitreomacular adhesion/traction. Retina (2015) 0.95
Efficacy of anti-vascular endothelial growth factor therapy in subretinal neovascularization secondary to macular telangiectasia type 2. Retina (2012) 0.92
Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients. Clin Ophthalmol (2010) 0.92
Genotypic analysis of cytomegalovirus retinitis poorly responsive to intravenous ganciclovir but responsive to the ganciclovir implant. Am J Ophthalmol (2003) 0.92
Mitochondrial DNA damage induced by 7-ketocholesterol in human retinal pigment epithelial cells in vitro. Invest Ophthalmol Vis Sci (2009) 0.90
Intraocular sustained-release delivery systems for triamcinolone acetonide. Pharm Res (2009) 0.90
Caspase-8, -12, and -3 activation by 7-ketocholesterol in retinal neurosensory cells. Invest Ophthalmol Vis Sci (2007) 0.89
Effects of Benzo(e)Pyrene, a toxic component of cigarette smoke, on human retinal pigment epithelial cells in vitro. Invest Ophthalmol Vis Sci (2008) 0.89
Optical coherence tomography in progressive outer retinal necrosis. Ophthalmic Surg Lasers Imaging (2006) 0.86
Outcomes associated with ganciclovir implants in patients with AIDS-related cytomegalovirus retinitis. Ophthalmology (2006) 0.85
The Implantable Miniature Telescope for macular degeneration. Curr Opin Ophthalmol (2006) 0.85
Activation of caspase-8 and caspase-12 pathways by 7-ketocholesterol in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci (2006) 0.85
Complement factor H polymorphism in age-related macular degeneration. Ophthalmology (2007) 0.85
Complications of ganciclovir implant surgery in patients with cytomegalovirus retinitis: the Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial. Retina (2004) 0.85
7-Ketocholesterol activates caspases-3/7, -8, and -12 in human microvascular endothelial cells in vitro. Microvasc Res (2008) 0.85
Emergence of drug-resistant cytomegalovirus retinitis in the contralateral eyes of patients with AIDS treated with ganciclovir. J Infect Dis (2004) 0.84
Faster visual recovery after 23-gauge vitrectomy compared with 20-gauge vitrectomy. Retina (2010) 0.83
Differential effects of nicotine on retinal and vascular cells in vitro. Toxicology (2009) 0.82
Drug delivery to the posterior segment of the eye. Eur J Ophthalmol (2011) 0.81
A single intraoperative sub-tenon's capsule injection of triamcinolone and ciprofloxacin in a controlled-release system for cataract surgery. Invest Ophthalmol Vis Sci (2009) 0.81
Macular edema. General pathophysiology. Dev Ophthalmol (2010) 0.81
Inhibition of apoptosis in human retinal pigment epithelial cells treated with benzo(e)pyrene, a toxic component of cigarette smoke. Invest Ophthalmol Vis Sci (2009) 0.81
Protective effects of memantine and epicatechin on catechol-induced toxicity on Müller cells in vitro. Toxicology (2010) 0.80
Toxicity of indocyanine green (ICG) in combination with light on retinal pigment epithelial cells and neurosensory retinal cells. Curr Eye Res (2005) 0.80
Vitreomacular disorders: pathogenesis and treatment. Retina (2012) 0.80
The effects of commercially available preservative-free FDA-approved triamcinolone (Triesence®) on retinal cells in culture. J Ocul Pharmacol Ther (2011) 0.80
Controlled transscleral drug delivery formulations to the eye: establishing new concepts and paradigms in ocular anti-inflammatory therapeutics and antibacterial prophylaxis. Expert Opin Drug Deliv (2010) 0.79
Effects of benzo(e)pyrene on the retinal neurosensory cells and human microvascular endothelial cells in vitro. Curr Eye Res (2009) 0.79
Evaluation of the toxicity of triamcinolone acetonide and dexamethasone sodium phosphate on human lens epithelial cells (HLE B-3). J Ocul Pharmacol Ther (2011) 0.78
Hydroquinone induces oxidative and mitochondrial damage to human retinal Müller cells (MIO-M1). Neurotoxicology (2013) 0.78
Effects of hydroquinone on retinal and vascular cells in vitro. Indian J Ophthalmol (2012) 0.77
Corticosteroids: Triamcinolone, Dexamethasone and Fluocinolone. Dev Ophthalmol (2015) 0.77
Hyaluronidase for pharmacologic vitreolysis. Dev Ophthalmol (2009) 0.76
In vitro evidence for mycophenolic acid dose-related cytotoxicity in human retinal cells. Retina (2013) 0.76
A preliminary evaluation of dexamethasone palmitate emulsion: a novel intravitreal sustained delivery of corticosteroid for treatment of macular edema. J Ocul Pharmacol Ther (2013) 0.76
Effects of dexamethasone on human trabecular meshwork cells in vitro. Graefes Arch Clin Exp Ophthalmol (2013) 0.76
Protective effects of lipoic acid on chrysene-induced toxicity on Müller cells in vitro. Mol Vis (2013) 0.75
Vitreous surgery in pigmented rabbits using the new, noncontact wide-field viewing system. Am J Ophthalmol (2004) 0.75
Intracellular Edema. Dev Ophthalmol (2017) 0.75
Advances in pharmacotherapy for wet age-related macular degeneration. Expert Opin Pharmacother (2015) 0.75
Use of Corticosteroids in the Treatment of Patients With Diabetic Macular Edema Who Have a Suboptimal Response to Anti-VEGF: Recommendations of an Expert Panel. Ophthalmic Surg Lasers Imaging Retina (2017) 0.75